Overactive Bladder - Results from #2220

Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder - Abstract April 11, 2012

Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases - Abstract April 9, 2012

Reproducibility of electrical sensory testing in lower urinary tract at weekly intervals in healthy volunteers and women with non-neurogenic detrusor overactivity - Abstract April 2, 2012

EAU 2012 - Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity (BO) – a prospective randomized double-blind study - Session Highlights March 30, 2012

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Health-related quality of life in patients with overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Prevalence and clinical features of detrusor underactivity among the community-dwelling elderly with lower urinary tract symptoms: A comparison between men and women - Session Highlights March 30, 2012

EAU 2012 - Value of nerve growth factor levels in overactive bladder syndrome – alterations after botulinum toxin therapy - Session Highlights March 30, 2012

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Poster March 30, 2012

EAU 2012 - Urethral versus suprapubic catheter for patients with spinal cord injury induced neurogenic bladder: A study applying the eleven-year comprehensive nationwide database of Taiwan - Session Highlights March 30, 2012

EAU 2012 - Urodynamics practice workshop - Session Highlights March 30, 2012

EAU 2012 - Injecting DIGNITY into your neurogenic detrusor overactivity (NDO) patient treatment paradigm: The role of botulinum toxin type A - Session Highlights March 30, 2012

Etiology of overactive bladder: A diet and lifestyle model for diabetes and obesity in older women - Abstract March 28, 2012

An overview of treatment of overactive bladder syndrome in women - Abstract March 19, 2012

Impact of overactive bladder treatment on associated comorbidities - Abstract March 16, 2012

Standard pharmacological treatment and new therapies for overactive bladder - Abstract March 14, 2012

Contemporary management of overactive bladder - Abstract March 9, 2012

Pathophysiology of overactive bladder - Abstract March 7, 2012

Solifenacin for overactive bladder: A systematic review and meta-analysis - Abstract March 6, 2012

Page 112 of 122